Electric fields with immunotherapy and chemo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 22 or older in the US, or 18 or older elsewhere.
- Diagnosed with stage 4 non-small cell lung cancer (squamous or non-squamous type).
- Have tumors in the chest that can be measured or seen on scans.
- Have not had any prior treatment for cancer that has spread.
- Good physical condition (able to do daily activities without help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a wearable device that uses electric fields (called tumor treating fields) before surgery for early-stage non-small cell lung cancer. The goal is to see if it can help shrink the tumor and improve outcomes for patients.
This trial tests a wearable device that sends electric fields (called Tumour Treating Fields) to the chest area, which may help slow or stop cancer growth. It is for people with non-small cell lung cancer that has a specific genetic change called EGFR mutation.
This study tests whether adding a type of chemotherapy called platinum-based chemo to an immunotherapy drug called tislelizumab helps people with advanced non-small cell lung cancer that has spread and has high PD-L1. The trial aims to see if this combination works better than immunotherapy alone in people with larger tumors.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
Hear when a new Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.